

## Europass Curriculum Vitae



### Personal information

**First name(s) / Surname(s)** **Marco Romano**  
**Address(es)** Corso V. Emanuele 416, 80135 Napoli, Italy  
**Telephone(s)** +39-0815666718 (office)                      Mobile: +393356768097  
**Fax(es)** (+39-0815666714  
**E-mail** marco.romano@unina2.it  
**Nationality** Italian  
**Date of birth** May 6<sup>th</sup>, 1953  
**Gender** Male

### Work experience

2015-Present Professor of Medicine-Gastroenterology, Head, Endoscopy Unit, Department of Clinical and Experimental Medicine and University Hospital, Università degli Studi della Campania "Luigi Vanvitelli"

2005-2015 Associate Professor of Gastroenterology and Staff Physician, Department of Clinical and Experimental Medicine and University Hospital, Second University of Naples, Italy

1984-2005 Staff Physician, Department of Clinical and Experimental Medicine and University Hospital, Second University of Naples, Italy

1990 -1991(May 1990-October 1991), 1993 (May-September) and 1999 (May-September) Visiting Professor, Vanderbilt University Medical School (Dr RJ Coffey's GI Laboratory)

1985-1988 Research Fellow, Long Beach VA medical Center-University of California Irvine (Dr KJ Ivey's GI Laboratory)

**Occupation or position held** Professor of Gastroenterology, Second University of Naples, Naples, Italy;  
**Main activities and responsibilities** Teaching, Research, Responsible of GI Endoscopy Unit, Responsible of out patient clinic for acid-related disorders, including H. pylori infection, functional GI disorders, coeliac disease, and inflammatory bowel diseases  
**Name and address of employer** Second University of Naples, Viale Beneduce 10, Caserta, Italy

### Education and training

**Dates** 1984 GI Fellowship (equivalent to board certificate) in Gastroenterology  
 1980-81 Training in Internal medicine  
 1980 MD Degree passed magna cum laude at Federico II University, Naples, Italy

Title of qualification awarded | MD

Principal subjects/occupational skills covered | GI research in acid related disorders, H. pylori-related diseases, Nutraceuticals and GI diseases  
Upper and lower endoscopy – Management of gastroesophageal reflux disease – Diagnosis and Management of inflammatory bowel diseases – Diagnosis and Management of H. pylori infection – Management of GI functional disorders

Name and type of organisation providing education and training | Federico II University, Naples, Italy; Pellegrini General Hospital, Naples, Italy

**Personal skills and competences**

Mother tongue | **Italian**

Other language | **English**

Self-assessment  
*European level* (\*)

**Language**

Understanding		Speaking		Writing			
Listening		Reading		Spoken interaction		Spoken production	
	Good		Good		Good		Good

(\*) [Common European Framework of Reference for Languages](#)

Social skills and competences | Silver Medal, Moscow Olympics, Saber team 1980  
Silver Medal Fencing World Championships, Saber Team, Grenoble 1974, Melbourne 1979

Driving licence | Driver licence A and B

**Annexes**

List of Publications  
Financial Grants for Research Activity  
Experience in Clinical trials

## Original Papers

- 1) Morphologic and functional damage of gastric mucosa in liver cirrhosis. C. Del Vecchio Blanco, N. Caporaso, A. Mele, **M. Romano**, A. Mancini, M. Pastore. *Panminerva Med* 20 : 70-77, 1983. **I.F.: 0.982**
- 2) Effect of L-Aminoacid solutions used to treat hepatic encephalopathy on gastric acid secretion. **M. Romano**, I. de Sio, M. Coltorti, C. Loguercio, C. Del Vecchio Blanco. *Br J Parent Ther* 7 : 34-38, 1986. **I.F.: n.d.**
- 3) Effect of somatostatin on salivary secretion in man. C. Loguercio, I. de Sio, **M. Romano**, C. Del Vecchio Blanco, M. Coltorti. *Digestion* 36 : 91-95, 1987. **I.F.: 1.94**
- 4) Human cell line for study of damage to gastric epithelial cells in vitro. **M. Romano**, M. Razandi, S. Sekhon, W.J. Krause, K.J. Ivey. *J Lab Clin Med*\*111 : 430-440, 1988. **I.F.: 3.490** \*ora  
**Translational Reseach**
- 5) Somatostatin stimulates prostaglandin production by rat gastric epithelial cells in vitro but is not cytoprotective. **M. Romano**, M. Razandi, K.J. Ivey. *Dig Dis Sci* 33:1435-1440, 1988. **I.F.: 2.26**
- 6) Acetaminophen directly protects human gastric epithelial cell monolayers against damage induced by sodium taurocholate. **M. Romano**, M. Razandi, K.J. Ivey. *Digestion* 40: 181-190, 1988. **I.F.: 1.94**
- 7) Effect of acute pentagastrin administration on salivary glands in rats. V. Esposito, G. Papaccio, **M. Romano**, C. Del Vecchio Blanco. *Arch Biol* 99: 397-402, 1988. **I.F.: n.d.**
- 8) Effect of calcium channel blocker diltiazem on cytoprotection and prostaglandin and sulfhydryl production by rat gastric epithelial cells. **M. Romano**, M. Razandi, K.J. Ivey. *HepatoGastroenterology* 35: 249-254, 1988. **I.F.: 0.77**
- 9) Protection of gastric epithelial cell monolayers from a human cell line by omeprazole in vitro. **M. Romano**, M. Razandi, K.J. Ivey. *Scand J Gastroenterol* 24: 513-521, 1989. **I.F.: 2.16**
- 10)Mild pancreatic damage in acute viral hepatitis. D. Taranto, A. Carrato, **M. Romano**, G. Maio, C.M. Izzo, C. Del Vecchio Blanco. *Digestion* 42: 93-97, 1989. **I.F.: 1.94**
- 11)Effect of cimetidine and ranitidine on drug-induced damage to gastric epithelial cell monolayers. **M. Romano**, M. Razandi, K.J. Ivey. *Gut* 30: 1313-1322, 1989. **I.F.: 10.73**
- 12)Effect of ranitidine on taurocholate-, ethanol-, and indomethacin-induced damage to gastric epithelial cells in vitro. **M. Romano**, M. Razandi, K.J. Ivey. *Digestion* 43: 212-221, 1989. **I.F.: 1.94**
- 13)Effect of sucralfate and its components on taurocholate-induced damage to rat gastric mucosal cells in tissue culture. **M. Romano**, M. Razandi, K.J. Ivey. *Dig Dis Sci* 35: 467-476, 1990. **I.F.: 2.26**
- 14)Effect of metoclopramide on transmural oesophageal variceal pressure and portal blood flow in cirrhotic patients. D. Taranto, R. Suozzo, I. de Sio, **M. Romano**, N. Caporaso, C. Del Vecchio Blanco, M. Coltorti. *Digestion* 47: 56-60, 1990. **I.F.: 1.94**
- 15)Familial clustering of hepatitis C virus infection and chronic liver disease. N. Caporaso, F. Morisco, **M. Romano**, A. Zembrino, M. Coltorti. *\*Ital J Gastroenterol* 22: 281-282, 1990. **I.F.: 3.16** \* ora  
**Digestive and Liver Diseases**
- 16)Role of sulfhydryl compounds in the defense of rat gastric epithelial cells against oxygen reactive metabolite-induced damage. **M. Romano**, M. Razandi, K.J. Ivey. *\*Ital J Gastroenterol* 23: 55-59, 1991. **I.F.: 3.16** \* ora  
**Digestive and Liver Diseases**
- 17)Hepatitis C virus infection is an additive risk factor for development of hepatocellular carcinoma in patients with liver cirrhosis. N. Caporaso, **M. Romano**, R. Marmo, I. de Sio, F. Morisco, A. Minerva, M. Coltorti. *J Hepatol* 12: 367-371, 1991. **I.F.: 9.86**
- 18)Regional variations in total and nonprotein sulfhydryl compounds in the human gastric mucosa and effect of ethanol. C. Loguercio, **M. Romano**, M. Di Sapio, G. Nardi, D. Taranto, C. Del Vecchio Blanco. *Scand J Gastroenterol* 26: 1042-1048, 1991 . **I.F.: 2.16**
- 19)Sulfhydryl mediation in protection of gastric mucosal cells in tissue culture by acetaminophen. **M. Romano**, M. Razandi, A. Raza, S. Szabo, K.J. Ivey. *\*Ital J Gastroenterol* 23: 481-486, 1991. **I.F.: 3.16** \* ora  
**Digestive and Liver Diseases**

- 20) Responsiveness to phenobarbital in an adult Crigler-Najjar case associated with neurological involvement and skin hyperextensibility. M. Persico, **M. Romano**, M. Muraca, S. Gentile. *Hepatology* 13: 213-215, 1991. *I.F.:* **12.0**
- 21) Cysteamine protects gastric epithelial cell monolayers against drug-induced damage: evidence for direct cellular protection by sulfhydryl compounds. **M. Romano**, M. Razandi, A. Raza, S. Szabo, K.J. Ivey. *Gut* 33: 30-38, 1992. *I.F.:* **10.73**
- 22) Transforming growth factor alpha protection against drug-induced damage to the rat gastric mucosa in vivo. **M. Romano**, W.H. Polk, J.A. Awad, C.L. Arteaga, L.B. Nanney, M.J. Wargovich, E.R. Krause, C.R. Boland, R.J. Coffey. *J Clin Invest* 90: 2409-2421, 1992. *I.F.:* **12.81**
- 23) Roles for transforming growth factor alpha in gastric physiology and pathophysiology. R.J. Coffey, **M. Romano**, W.H. Polk, P.J. Dempsey. *Yale J Biol Med* 65: 693-704, 1992. *I.F.:* **0.381**
- 24) Glutathione prevents ethanol-induced gastric mucosal damage and depletion of sulfhydryl compounds in humans. C. Loguercio, D. Taranto, F. Beneduce, C. Del Vecchio Blanco, A. De Vincentiis, G. Nardi, **M. Romano**. *Gut* 34: 161-165, 1993. *I.F.:* **10.73**
- 25) Decision-making model for a non-invasive diagnosis of compensated liver cirrhosis. R. Marmo, **M. Romano**, I. de Sio, N. Caporaso, M. Persico, M. Coltorti. *\*Ital J Gastroenterol* 25: 1-8, 1993. *I.F.:* **3.16 \* ora Digestive and Liver Diseases**
- 26) Cytotoxicity of *Helicobacter pylori* cytotoxin on human gastric epithelial cells in vitro: role of cytotoxin (s) and ammonia. V. Ricci, P. Sommi, R. Fiocca, E. Cova, N. Figura, **M. Romano**, K.J. Ivey, E. Solcia, U. Ventura. *Eur J Gastroenterol Hepatol* 5: 687-694, 1993. *I.F.:* **1.96**
- 27) Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. N. Caporaso, R. Suozzo, F. Morisco, M. D'Antonio, **M. Romano**, M. Coltorti. *\*Ital J Gastroenterol* 25: 482-486, 1993. *I.F.:* **3.16 \* ora Digestive and Liver Diseases**
- 28) Na<sup>+</sup>,K<sup>+</sup>-ATPase of gastric cells: a target of *Helicobacter pylori* cytotoxic activity. V. Ricci, P. Sommi, E. Cova, R. Fiocca, **M. Romano**, K.J. Ivey, E. Solcia, U. Ventura. *FEBS Lett* 334: 158-160, 1993. *I.F.:* **3.58**
- 29) Effect of transforming growth factor alpha on gastric acid secretion in rats and monkeys. A. Guglietta, C.A. Lesch, **M. Romano**, R.W. McClure, R.J. Coffey. *Dig Dis Sci* 39: 177-182, 1994. *I.F.:* **2.26**
- 30) Gastric endoscopic features in patients with liver cirrhosis: Correlation with oesophageal varices, intravariceal pressure, and liver dysfunction. D. Taranto, R. Suozzo, **M. Romano**, N. Caporaso, C. Del Vecchio Blanco, M. Coltorti. *Digestion* 55: 115-120, 1994. *I.F.:* **1.94**
- 31) The association between Rifamycin-SV (R-SV) related hyperbilirubinemia and antipyrine clearance as a new test of liver function in cirrhosis. M. Persico, **M. Romano**, N. Villano, F. Montella, S. Gentile. *Eur J Clin Invest* 24: 201-204, 1994. *I.F.:* **3.36**
- 32) Comparison between transforming growth factor alpha and epidermal growth factor in the protection of rat gastric mucosa against drug-induced injury. **M. Romano**, E.R. Krause, C.R. Boland, R.J. Coffey. *\*Ital J Gastroenterol* 26: 223-228, 1994. *I.F.:* **3.16 \* ora Digestive and Liver Diseases**
- 33) Prevalence of hepatitis C virus infection in the household contacts of patients with HCV-related chronic liver disease. M. Coltorti, N. Caporaso, F. Morisco, R. Suozzo, **M. Romano**, M. D'Antonio. *Infection* 22: 183-185, 1994. *I.F.:* **2.44**
- 34) Expression of insulin-like growth factor (IGF)-II and IGF-I receptor during proliferation and differentiation of Caco-2 human colon carcinoma cells. R. Zarrilli, S. Pignata, **M. Romano**, A. Gravina, S. Casola, C.B. Bruni, A. Acquaviva. *Cell Growth & Diff (ora Mol Cancer Res)* 5: 1085-1091, 1994. *I.F.:* **4.35**
- 35) Regional distribution of transforming growth factor alpha and epidermal growth factor in the normal and portal hypertensive gastroduodenal mucosa. **M. Romano**, K.S. Meise, R. Suozzo, G. Sessa, M. Persico, R.J. Coffey. *Dig Dis Sci* 40: 263-267, 1995. *I.F.:* **2.26**
- 36) Hepatitis C virus-RNA in serum and liver histology in asymptomatic anti-HCV positive subjects. M. Coltorti, **M. Romano**, M. Persico, F. Morisco, C. Tuccillo, N. Caporaso. *Infection* 23:33-35, 1995. *I.F.:* **2.44**

- 37) Ultrasound guided fine needle aspiration biopsy of portal vein thrombosis in liver cirrhosis: results in 15 patients. I. de Sio, L. Castellano, M. Calandra, **M. Romano**, M. Persico, C. Del Vecchio-Blanco. *J Gastroenterol Hepatol* 10: 662-665, 1995. *I.F.:* **3.32**
- 38) Constitutive IGF-II expression interferes with the enterocyte-like differentiation of CaCo-2 cells. R. Zarrilli, **M. Romano**, S. Pignata, S. Casola, C.B. Bruni, A.M. Acquaviva. *J Biol Chem* 271: 8108-8114, 1996. *I.F.:* **4.65**
- 39) Increased gastroduodenal concentrations of transforming growth factor alpha in adaptation to aspirin in monkeys and rats. **M. Romano**, C. Lesch, K.S. Meise, M. Veljaca, B. Sanchez, E.R. Krause, C.R. Boland, A. Guglietta, R.J. Coffey. *Gastroenterology* 110: 1446-1455, 1996. *I.F.:* **12.82**
- 40) Activation of fetal promoters of insulin-like growth factor II gene in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma. G. Nardone, **M. Romano**, A. Calabrò, P.V. Pedone, I. de Sio, M. Persico, G. Budillon, C.B. Bruni, R. Zarrilli. *Hepatology* 23: 1304-1312, 1996. *I.F.:* **12.0**
- 41) Histamine H<sub>2</sub> receptor antagonists stimulate proliferation but not migration of human gastric mucosal cells in vitro. C. Ciacci, R. Zarrilli, V. Ricci, A. De Luca, G. Mazzacca, C. Del Vecchio Blanco, **M. Romano**. *Dig Dis Sci* 45: 972-978, 1996. *I.F.:* **2.26**
- 42) Significance of ammonia in the genesis of gastric lesions induced by *Helicobacter pylori* - An in vitro study with different bacterial strains and urea concentrations. P. Sommi, V. Ricci, R. Fiocca, **M. Romano**, K.J. Ivey, E. Cova, E. Solcia, U. Ventura. *Digestion* 57: 299-304, 1996. *I.F.:* **1.94**
- 43) Effect of *Helicobacter pylori* on gastric epithelial cell migration and proliferation in vitro: role of VacA and CagA. V. Ricci, C. Ciacci, R. Zarrilli, P. Sommi, M.K.R. Tummuru, C. Del Vecchio Blanco, C.B. Bruni, T.L. Cover, M.J. Blaser, **M. Romano**. *Infect Immun* 64: 2829-2833, 1996. *I.F.:* **4.07**
- 44) Ultrasound-guided percutaneous ethanol injection: first choice for treatment of hepatocellular carcinoma in the elderly. I. de Sio, L. Castellano, M. Calandra, M. Persico, **M. Romano**, R. Torella, C. Del Vecchio Blanco. *Arch Gerontol Geriatr* suppl 5: 295-303, 1996. *I.F.:* **1.70**
- 45) *Helicobacter pylori* vacuolating toxin accumulates into the endosomal-vacuolar compartment of cultured gastric cells and potentiates the vacuolating activity of ammonia. V. Ricci, P. Sommi, R. Fiocca, **M. Romano**, E. Solcia, U. Ventura. *J Pathol* 183: 453-459, 1997. *I.F.:* **7.58**
- 46) *Helicobacter pylori* up-regulates the expression of epidermal growth factor-related peptides but inhibits their proliferative effect in MKN 28 gastric mucosal cells. **M. Romano**, V. Ricci, A. Di Popolo, P. Sommi, C. Del Vecchio Blanco, C.B. Bruni, U. Ventura, T.L. Cover, M.J. Blaser, R.J. Coffey, R. Zarrilli. *J Clin Invest* 101: 1604-1613, 1998. *I.F.:* **12.81**
- 47) Persistence of *Helicobacter pylori* VacA toxin and vacuolating potential in cultured gastric epithelial cells. P. Sommi, V. Ricci, R. Fiocca, V. Necchi, **M. Romano**, J.L. Telford, E. Solcia, U. Ventura. *Am J Physiol* 275: G681-G688, 1998. *I.F.:* **3.65**
- 48) *Helicobacter pylori* up-regulates cyclooxygenase-2 mRNA expression and prostaglandinE-2 synthesis in MKN 28 gastric mucosal cells in vitro. **M. Romano**, V. Ricci, A. Memoli, C. Tuccillo, A. Di Popolo, P. Sommi, A.M. Acquaviva, C. Del Vecchio Blanco, C.B. Bruni, R. Zarrilli. *J Biol Chem* 273: 28560-28563, 1998. *I.F.:* **4.65**
- 49) Prevalence of anti-microbial resistance in eighty clinical isolates of *Helicobacter pylori*. M.R. Iovene, **M. Romano**, A.P. Pilloni, B. Giordano, F. Montella, S. Caliendo, M.A. Tufano. *Chemotherapy* 45: 8-14, 1999. *I.F.:* **2.07**
- 50) Up-regulation of IL-17 is associated with bioactive IL-8 expression in *Helicobacter pylori*-infected human gastric mucosa. F. Luzza, T. Parrello, G. Monteleone, L. Sebkova, **M. Romano**, R. Zarrilli, M. Imeneo, F. Pallone. *J Immunol* 165: 5332-5337, 2000. *IF:* **5.52**
- 51) *In vivo* and *in vitro* studies of cytosolic phospholipase A2 expression in *Helicobacter pylori* infection. G. Nardone, E.I. Holicky, J.R. Uhl, L. Sabatino, S. Staibano, A. Rocco, V. Colantuoni, B.A. Manzo, **M. Romano**, G. Budillon, F.R. Cockerill III, L.J. Miller. *Infect Immun* 69: 5857-5863, 2001. *IF:* **4.07**
- 52) Alteration of haemostasis in nonmetastatic gastric cancer. P. Di Micco, **M. Romano**, A. Niglio, P. Nozzolillo, A. Federico, P. Petronella, L. Nunziata, B. Di Micco., R. Torella. *Dig Liver Dis* 33: 546-550, 2001. *IF:* **3.16**


- 53) Extracellular pH modulates *Helicobacter pylori*-induced vacuolation and VacA toxin internalization in human gastric epithelial cells. V Ricci., P.Sommi, R. Fiocca, V.Necchi, **M. Romano**, E. Solcia. **Biochem Biophys Res Comm** 292: 167-174, 2002. **IF: 2.41**
- 54) NSAIDs counteract *Helicobacter pylori* VacA toxin-induced cell vacuolation in MKN 28 gastric mucosal cells. V. Ricci, B. A. Manzo, P. Sommi, C. Tuccillo, P. Boquet, **M. Romano**, R. Zarrilli. **Am J Physiol** 283: G511-G520, 2002. **IF: 3.65**
- 55) Up-regulation of heparin binding epidermal growth factor-like growth factor and amphiregulin in *Helicobacter pylori*-infected human gastric mucosa. C. Tuccillo, B.A. Manzo, G. Nardone, G. D'Argenio, A. Rocco, A. Di Popolo, N. Della Valle, S. Staibano, G. De Rosa., V. Ricci, C. Del Vecchio Blanco, R. Zarrilli, **M. Romano**. **Digest Liv Dis** 34: 498-505, 2002 . **IF.: 3.16**
- 56) Reflux oesophagitis in adult coeliac disease: beneficial effect of gluten-free diet. A Cuomo, **M Romano**, A Rocco, G Budillon, C Del Vecchio Blanco, G Nardone. **Gut** 53: 514-517, 2003. **IF.: 10.73** **AC e MR Uguali Contributori**
- 57) *Helicobacter pylori* VacA toxin up-regulates VEGF expression in MKN 28 gastric cells through an EGF receptor-, cyclooxygenase-2-dependent mechanism. R Caputo, Concetta Tuccillo, BA Manzo, R Zarrilli, G Tortora, C Del Vecchio Blanco, V Ricci, F Ciardiello, **M Romano**. **Clin Cancer Res** 9: 2015-2021, 2003 . **IF.: 7.84**
- 58) Pretreatment antimicrobial susceptibility testing is cost-saving in the eradication of *Helicobacter pylori*. **M Romano**, R Marmo, A Cuomo, T De Simone, C Mucherino, M R Iovene, F Montella, M Tufano, C Del Vecchio Blanco, G Nardone. **Clin Gastroenterol Hepatol** 1: 273-278, 2003. **IF: 6.65**
- 59) Vitamin A deficiency alters the bioelectric parameters and RNA content of rat gastric mucosa *in vivo*. U. Ventura, T. Ceriani, E. Montini, **M. Romano**, V. Ricci. **J Physiol Pharmacol** 54: 523-532, 2003. **IF: 2.48**
- 60) *Helicobacter pylori*  $\alpha$ -glutamyltranspeptidase upregulates COX-2 and EGF-related peptide expression in human gastric cells. I. Busiello, R. Acquaviva, A. Di Poopolo, T.G. Blanchard, V. Ricci, **M. Romano**, R. Zarrilli. **Cell Microbiol** 6: 255-267, 2004. **IF: 4.81**
- 61) Induction and regulation of Smad7 in the gastric mucosa of patients with *Helicobacter pylori* infection. G Monteleone, G Del Vecchio Blanco, G Palmieri, P Vavassori, I Monteleone, A Colantoni, S Battista, LG Spagnoli, **M Romano**, M Borrelli, TT MacDonald, F Pallone. **Gastroenterology** 126: 674-682, 2004. **IF: 12.82**
- 62) Apple polyphenol extracts prevent damage to human gastric epithelial cells *in vitro* and to rat gastric mucosa *in vivo*. G. Graziani, G. D'Argenio, C. Tuccillo, C. Loguercio, A. Ritieni, F. Morisco, C. Del Vecchio Blanco, V. Fogliano, **M. Romano**. **Gut** 54: 193-200, 2005. **IF: 10.73**
- 63) A randomized controlled trial of acarbose in hepatic encephalopathy. S. Gentile, G. Guarino, **M. Romano**, I. A. Alagia, M. Fierro, S. Annunziata, P. L. Magliano, R. Torella. **Clin Gastroenterol Hepatol** 3:184-191, 2005. **IF: 6.65**
- 64) Antitumor activity of ZD6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. C. Tuccillo, **M. Romano**, T. Troiani, E. Martinelli, F. Morgillo, F. De Vita, R. Bianco, G. Fontanini, R.A. Bianco, G. Tortora, F. Ciardiello. **Clin Cancer Res** 15: 1268-1276, 2005. **IF: 7.84**
- 65) Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for *Helicobacter pylori* eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. G. Manes, O. Pieramico, F. Perri, D. Vaira, N. Giardullo, **M. Romano**, G. Nardone, A. Balzano. **Dig Dis Sci** 50: 443-448, 2005. **IF: 2.26**
- 66) Vascular endothelial growth factor and neo-angiogenesis in *H. pylori* gastritis in humans. C. Tuccillo, A. Cuomo, A. Rocco. E. Martinelli, S. Staibano, M. Mascolo, A.G. Gravina, G. Nardone, V. Ricci, F. Ciardiello, C. Del Vecchio Blanco, **M. Romano**. **J Pathol** 207: 277-284, 2005. **IF: 7.58**
- 67) Free-soluble and outer membrane vesicle-associated VacA from *Helicobacter pylori*: two forms of release, a different activity. V. Ricci, V. Chiozzi, V. Necchi, A. Oldani, **M. Romano**, E. Solcia, U. Ventura. **Biochem Biophys Res Commun** 337: 173-178, 2005. **IF: 2.41**.
- 68) Central serous chorioretinopathy and *Helicobacter pylori*. L. Cotticelli, M. Borrelli, A.A. D'Alessio, M. Menzione, A. Villani, G. Piccolo, F. Montella, M.R. Iovene, **M. Romano**. **Eur J Ophthalmol** 16: 274-278; 2006. **IF: 0.91**

- 69) Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. M.P. Morelli, T. Cascone T, T. Troiani, C. Tuccillo, R. Bianco, N. Normanno, **M. Romano**, B.M. Veneziani, G. Fontanini, S.G. Eckhardt, S. De Placido, G. Tortora, F. Ciardiello. *J Cell Physiol* 10: 344-353, 2006. **IF: 4.22**
- 70) Vascular endothelial growth factor and cyclooxygenase-2 are over-expressed in ileal pouch-anal anastomosis. **M Romano**, A Cuomo, C Tuccillo, R Salerno, A Rocco, S Staibano, M Mascolo G Sciaudone, C Mucherino, A Giuliani, G Riegler, G Nardone, C Del Vecchio Blanco, F Selvaggi. *Dis Col Rect* 50: 660-669, 2007. **IF:3.34**
- 71) Interleukin-21 is highly produced in *Helicobacter pylori*-infected gastric mucosa and promotes gelatinases synthesis. R. Caruso, D. Fina, I. Peluso, M.C. Fantini, C. Tosti, G. Del Vecchio Blanco, O.A. Paoluzi, F. Caprioli, F. Andrei, C. Stolfi, **M. Romano**, V. Ricci, T.T. MacDonald, F. Pallone, G. Monteleone. *J Immunol* 178: 5957-5965, 2007. **IF: 5.52**
- 72) Annurca apple polyphenols have potent demethylating activity and can reactivate silenced tumor suppressor genes in colorectal cancer cells. L. Fini, M. Selgrad, V. Fogliano, G. Graziani, **M. Romano**, E. Hotchkiss, Y. A. Daoud, E. B. De Vol, C.R. Boland, L. Ricciardiello. *J Nutr* 137:2622-2628, 2007. **IF 4.2**
- 73) Chemopreventive properties of pinoresinol-rich olive oil involve a selective activation of the ATM-p53 cascade in colon cancer cell lines. L. Fini, E. Hotchkiss, V. Fogliano, G. Graziani, **M Romano**, EB De Vol, H Qin, M Selgrad, CR Boland, L. Ricciardiello. *Carcinogenesis* 29: 139-146, 2008. **IF 5.63.**
- 74) Apple polyphenol extracts prevent aspirin-induced damage to the rat gastric mucosa. G. D'Argenio, G. Mazzone, C. Tuccillo, I. Grandone, A.G. Gravina, G. Graziani, V. Fogliano, **M. Romano**. *Br J Nutr* 100: 1228-1236, 2008. **IF 3.30.**
- 75) Interleukin-13 mucosal production in *Helicobacter pylori*-related gastric diseases. B Marotti, A Rocco, P De Colibus, D Compare, G de Nucci, S Staibano, F Tatangelo, **M Romano**, G Nardone. *Dig Liv Dis* 40: 240-247, 2008. **IF 3.16.**
- 76) Antiviral therapy after complete response to chemotherapy could be of efficacy in HCV positive non-Hodgkin lymphoma. V. La Mura, A. De Renzo, F. Perna, D. D'Agostino, M. Masarone, **M. Romano**, B. Savino, R. Torella, M. Persico. *J Hepatol* 49: 557-563, 2008. **IF: 9.86.**
- 77) Failure of first line eradication treatment significantly increases prevalence of anti-microbial resistant *Helicobacter pylori* clinical isolates. **M. Romano**, M.R. Iovene, M.I. Russo, A. Rocco, R. Salerno, D. Cozzolino, AP Pilloni, M.A. Tufano, D. Vaira, G. Nardone. *J Clin Pathol* 61: 1112-1115, 2008. **IF: 2.44.**
- 78) Relationship between VacA toxin and ammonia in *Helicobacter pylori*-induced apoptosis in human gastric epithelial cells. V. Chiozzi, G. Mazzini, A. Oldani, U. Ventura, **M. Romano**, P. Boquet, V. Ricci. *J Physiol Pharmacol* 60: 23-30, 2009. **IF: 2.48**
- 79) The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. Federico A, Tuccillo C, Grossi E, Abbiati R, Garbagna N, **Romano M**, Tiso A, Blanco C del V, Loguercio C. *Eur Rev Med Pharmacol Sci* 13:285-293, 2009. **IF: 1.09**
- 80) *Helicobacter pylori* Hp(2-20) promotes migration and proliferation of gastric epithelial cells by interacting with formyl peptide receptors in vitro and accelerates gastric mucosal healing in vivo. de Paulis A, Prevete N, Rossi FW, Rivellese F, Salerno F, Delfino G, Liccardo B, Avilla E, Montuori N, Mascolo M, Staibano S, Melillo RM, D'Argenio G, Ricci V, **Romano M**, Marone G. *J Immunol* 183:3761-3769; 2009. **IF: 5.52.**
- 81) Alcoholic beverages and gastric epithelial cell viability: effect on oxidative stress-induced damage. Loguercio C, Tuccillo C, Federico A, Fogliano V, Del Vecchio Blanco C, **Romano M**. *J Physiol Pharmacol* 60 (suppl 7): 87-92, 2009. **IF: 2.48**
- 82) Empiric levofloxacin-containing vs clarithromycin-containing sequential therapy for *Helicobacter pylori* eradication: a randomized trial. **Romano M**, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A, Salerno R, Marmo R, Federico A, Nardone G. *Gut* 59: 1465-1470, 2010 **IF: 10.73**

- 83) Prevalence of nonpolypoid colorectal neoplasia: an Italian multicenter observational study. Bianco MA, Cipoletta L, Rotondano G, Buffoli F, Gizzi G, Tessari F,..... Romano M on behalf of the Flat Lesions Italian Network (FLIN). **Endoscopy** 42: 279-285, 2010. **IF: 5.73**
- 84) Effects of long-term PPI treatment on producing bowel symptoms and SIBO. D Compare, L Pica, A Rocco, F De Giorgi, R Cuomo, G Sarnelli, **M Romano\***, G Nardone\*. **Eur J Clin Invest** 41: 380-386, 2011. **IF: 3.36. \* Equal contributors**
- 85) Global DNA hypomethylation is an early event in *H. pylori*-related gastric carcinogenesis. \*Compare D, \*Rocco A, Liguori E, D'Armiento FP, Persico G, Masone S, Coppola-Bottazzi E, Suriani R, **\*Romano M**, \*Nardone. **J Clin Pathol** 64: 677-682, 2011 **IF: 2.44. \*Equal contributors.**
- 86) Chemoprevention of intestinal polyps in ApcMin/+ mice fed western or balanced diets by drinking Annurca apple polyphenol extract. L Fini, G Piazza, Y Daoud, M Selgrad, S Maegawa, M Garcia, V Fogliano, **M Romano**, G Graziani, P Vitaglione, SW Carmack, A Gasbarrini, RM Genta, J-P J Issa, CR Boland, Ricciardiello L. **Cancer Prev Res** 4: 907-915, 2011. **IF: 4.89**
- 87) Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. G Piazza, L Fini, M Selgrad, M Garcia, Y Daoud, T Wex, P Malfertheiner, A Gasbarrini, **M Romano**, R M Genta, JFox, CR Boland, F Bazzoli, L Ricciardiello. **Oncotarget** 2:1291-1301, 2011. **IF: 6.64.**
- 88) Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. G D'Argenio, G Mazzone, C Tuccillo, MT Ribecco, G Graziani, AG Gravina, S Caserta, S Guido, V Fogliano, N Caporaso, **M Romano**. **Dig Liver Dis**; 44: 555-562, 2012. **IF 3.16.**
- 89) Risk factors for inflammatory bowel diseases according to the "hygiene hypothesis": A case-control, multi-centre, prospective study in Southern Italy. Castiglione F, Diaferia M, Morace F, Labianca O, Meucci C, Cuomo A, Panarese A, **Romano M**, Sorrentini I, D'Onofrio C, Caporaso N, Rispo A. **J Crohn's Colitis** 6:324-329, 2012. **IF: 3.39.**
- 90) Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of *Helicobacter pylori* infection. A Federico, G Nardone, A G Gravina, M R Iovene, A Miranda, D Compare, P A Piloni, A Rocco, L Ricciardiello, R Marmo, C Loguercio, **M Romano**. **Gastroenterology** 143:55-61, 2012. **IF: 12.82**
- 91) Celiac disease and C virus-related chronic hepatitis: a nonassociation. Gravina AG, Federico A, Masarone M, Cuomo A, Tuccillo C, Loguercio C, Persico M, **Romano M**. **BMC Res Notes** 5:533, 2012.
- 92) Percutaneous endoscopic gastrostomy for critically ill patients in a general intensive care unit. F. Ferraro\*, A G Gravina\*, A d'Elia, P Esposito, C Vitiello, M Dallio, L Romano, C Loguercio, **M Romano\***, A Federico\*. **Acta Gastroenterol Belg** 76:306-310; 2013.. \* equally contributed to the manuscript **IF: 0.58**
- 93) Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage? D'Argenio G; Cariello R; Tuccillo C; Mazzone G; Federico A; Funaro A; De Magistris L; Grossi E; Callegari ML; Chirico M; Caporaso N; **Romano M**; Morelli L; Loguercio C. **Liver Int** 33: 687-697, 2013. **IF: 3.87**
- 94) *Helicobacter pylori* Hp(2-20) induces eosinophil activation and accumulation in superficial gastric mucosa and stimulates VEGF-A and TGF- $\beta$  release by interacting with formyl-peptide receptors. N. Prevede, F.W. Rossi, F. Rivellese, D. Lamacchia, C. Pelosi, A. Lobasso, V. Necchi, E. Solcia, R. Fiocca, P. Ceppa, S. Staibano, M. Mascolo, G. D'Argenio, **Romano M**, V. Ricci, G. Marone and A. de Paulis. **Int J Immunopathol Pharmacol** 26:647-662, 2013. **IF: 2.51.**
- 95) Ultrasound-guided percutaneous biopsy for diagnosis of gastrointestinal lesions. I. de Sio, A. Funaro, LM Vitale, M. Niosi, G Francica, A Federico, D Sgambato, C. Loguercio, **M. Romano**. **Dig Liver Dis** 45:816-819; 2013. **IF 3.16**
- 96) Optimized nonbismuth quadruple therapies cure most patients with *Helicobacter pylori* infection in populations with high rates of antibiotic resistance. J Molina-Infante, **M Romano**, M Fernandez Bermejo, A Federico, AG Gravina, L Pozzati, E Garcia-Abadia, G Vinagre-Rodriguez, C Martinez-Alcala, M Hernandez-Alonso, A Miranda, MR Iovine, C Pazos-Pacheco, JP Gisbert. **Gastroenterology** 145:121-128; 2013. **IF 12.82**
- 97) Hashimoto's thyroiditis and entero-chromaffin-like cell hyperplasia: early detection and somatostatin analogue treatment. A Renzullo, G Accardo, D Esposito, A De Bellis, A Bizzarro, M



- Romano, A Federico, AG Gravina, G Conzo, G Pannone, A Faggiano, A Colao, D Pasquali. *Eur J Inflamm* 11: 863-870; 2013. **IF: 0.99**
- 98) Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. Masarone M, De Renzo A, La Mura V, Sasso FC, **Romano M**, Signoriello G, Rosato V, Perna F, Pane F, Persico M. *BMC Gastroenterol* 14:31, 2014; **IF: 2.11**
- 99) Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. **Federico A**, Zappavigna S, **Romano M**, Grieco P, Luce A, Marra M, Gravina AG, Stiuso P, D'Armiento FP, Vitale G, Tuccillo C, Novellino E, Loguercio C, Caraglia M. *Eur J Clin Invest* 44:285-294, 2014. **IF: 3.36**
- 100) Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. G Piazzi, G D'Argenio, A Prossomariti, V Lembo, G Mazzone, M Candela, E Biagi, P Brigidi, P Vitaglione, V Fogliano, A Munarini, A Belluzzi, C Ceccarelli, P Chieco, T Balbi, P M Loadman, M A Hull, **M Romano**, F Bazzoli, L Ricciardiello. *Int J Cancer* 135:2004-2013, 2014. **IF 6.2**
- 101) A Facebook survey to obtain alcohol-related information by young people and adolescents. An Italian study. Zulli C, Federico A, Gaeta L, Del Prete A, Iadevaia M, Gravina AG, Romano M, Loguercio C. *Acta Gastroenterol Belg* 2014; 77: 18-24. **IF: 0.58**
- 102) Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: a single-center retrospective study. I. de Sio, LM Vitale, M Niosi, A Del Prete, C de Sio, L Romano, A Funaro, R Meucci, A Federico, C Loguercio, **Romano M**. *United European Gastroenterol J* 2: 279-287, 2014. **IF: 2.08**
- 103) Detection of gastric precancerous conditions in daily clinical practice: a nationwide survey. Lehener E, Zullo A, Hassan C, Perri F, Dinis-Ribeiro M, Esposito G, Di Giulio E, Buscarini E, Bianco MA, De Boni M, MAG-study group, **Romano M**, Annibale B. *Helicobacter* 19:417-424, 2014. **IF: 3.511**
- 104) Prevalence of lesions detected at upper endoscopy: an Italian Survey. Zullo A, Esposito G, and AIGO-SIED study Group., **Romano M**, Annibale B. *Eur J Intern Med* 25:772-776, 2014. **IF: 2.05**
- 105) Use of larvae of the wax moth *Galleria mellonella* as an in vivo model to study the virulence of *Helicobacter pylori*. Giannouli M, Palatucci AT, Rubino V, Ruggiero G, **Romano M**, Triassi M, Ricci V, Zarrilli R. *BMC Microbiol* 2014; 14:228. **IF: 2.98**
- 106) Two-week, high-dose proton pump inhibitor, moxifloxacin triple *Helicobacter pylori* therapy after failure of standard triple or non-bismuth quadruple treatments. Gisbert JP, **Romano M**, Molina Infante J et al. *Dig Liver Dis* 47:108-113, 2014. **IF: 3.16**
- 107) The patterns of reflux can affect regression of non-dysplastic and low-grade dysplastic Barrett's esophagus after medical and surgical treatment. A prospective case-control study. **S.Tolone**, P. Limongelli, M Romano, A Federico, G Docimo, R Ruggiero, L Bruscianno, G Del Genio, L Docimo. *Surg Endosc* 29:648-657, 2015 **IF: 3.427**
- 108) *Helicobacter pylori* infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. Gravina AG, Federico A, Ruocco E, Lo Schiavo A, Masarone M, Tuccillo C, Peccerillo F, Miranda A, Romano L, de Sio C, de Sio I, Persico M, Ruocco V, Riegler G Loguercio C, Romano M. *United Eur Gastroenterol J* 3: 17-24, 2015. **IF: 2.08**
- 109) *Helicobacter pylori* second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy after failure of standard triple or non-bismuth quadruple treatments. JP. Gisbert, **M Romano**, A G. Gravina, P Solís-Muñoz, F Bermejo, J Molina-Infante, M Castro-Fernández, J Ortuño, A J. Lucendo, M Herranz<sup>1</sup>, I Modolell, F del Castillo, J Góme, A. Miranda, M. Martorano, A Algaba, M Pabón, T Angueira, L Fernández-Salazar, A Federico, J Barrio, B Velayos, B Gómez, J L Domínguez, A C. Marín, A G. McNicholl. *Aliment Pharmacol Ther* 2015; 41: 768-775. **IF: 4.55**
- 110) A pilot study on the ability of clinoptilolite to absorb ethanol *in vivo* in healthy drinkers: effect of gender. Federico A, Dallio M, Gravina AG, Paura C, Romano M, Rossetti G, Somalvico F, Tuccillo C, Loguercio C. *J Physiol Pharmacol* 2015 66:441-447. **IF: 2.48**

- 111) Incidence and distribution of coeliac disease in Campania (Italy): 2011-2013. Zingone F, West J, Auricchio R, ....Romano M,..... Ciacci C. **United Eur Gastroenterol J** 2015; 32: 182-189. **IF: 2.08**
- 112) Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Federico A, Loguercio C, de Sio I, Gravina AG, De Vita F, Dallio M, Romano M, Ciardiello F. **Oncol Lett.** 2015;9:1628-1632
- 113) Quality of bowel cleansing in hospitalized patients undergoing colonoscopy: A multicentre prospective regional study. Rotondano G, Rispo A, Bottiglieri ME, De Luca L, Lamanda R, Orsini L, Bruzzese D, Galloro G; SIED Campania PISCoPO study group investigators, Romano M, Miranda A, Loguercio C, Esposito P, Nardone G, Compare D, Magno L, Ruggiero S, Imperatore N, De Palma GD, Gennarelli N, Cuomo R, Passananti V, Cirillo M, Cattaneo D, Bozzi RM, D'Angelo V, Marone P, Riccio E, De Nucci C, Monastra S, Caravelli G, Verde C, Di Giorgio P, Giannattasio F, Capece G, Taranto D, De Seta M, Spinosa G, De Stefano S, Familiari V, Cipolletta L, Bianco MA, Sansone S, Galasso G, De Colibus P, **Romano M**, Borgheresi P, Ricco G, Martorano M, Gravina AG, Marmo R, Rea M, Maurano A, Labianca O, Colantuoni E, Bottiglieri ME, Iuliano D, Trovato C, Fontana A, Pasquale L, Morante A, Perugini B, Scaglione G. **Dig Liver Dis** 2015; 47:669-674. **IF: 3.16**
- 114) Guidelines for the management of *Helicobacter pylori* infection in Italy - The III Working Group Consensus Report 2015. R M Zagari, **M Romano**, V Ojetti, R Stockbrugger, S Gullini, B Annibale, F Farinati, E Ierardi, G Maconi, M Rugge, C Calabrese, F Di Mario<sup>1</sup>, F Lizza, S Pretolani, A Savio, G Gasbarrini, M Caselli. **Dig Liver Dis** 2015; 47:903-912. **IF: 3.16**
- 115) Rapid virological response represents the highest predictor factor of response to antiviral treatment in HCV-related chronic hepatitis: a multicenter retrospective study. Federico A, Masarone M, **Romano M**, Dallio M, Rosato V, Persico M. **Hepat Mon** 2015; 15 (6): e18640 **IF: 1.24**
- 116) The burden of anaemia in patients with inflammatory bowel diseases. A Testa  A Rispo, M Romano, G Riegler, F Selvaggi, E Bottiglieri, M Martorano, M Rea, A G Gravina, O M Nardone, M Patturelli, G Pellino, A Miranda, N Caporaso, F Castiglione. **Dig Liver Dis** 2016; 48:267-270. **IF: 3.16**
- 117) Lispro insulin in people with non-alcoholic liver cirrosi and type 2 diabetes mellitus. Gentile S, Guarino G, Strollo F, **Romano M**, Genovese S, Masarone M, Ceriello A. **Diabetes Res Clin Pract** 2016; 113:179-186. **IF: 2.5**
- 118) Predictive biomarkers along gastric cancer patogenetic pathways. Panarese I, De Vita F, Ronchi A, **Romano M**, Alfano R, Di Martino N, Zito F, Ferraraccio F, Franco R. **Exp Rev Anticancer Ther** 2017; DOI:10.1080/14737140.2017.1301207
- 119) Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis. S Jeong, E Choi, CP Petersen, JT Roland, A Federico, R Ippolito, FP D'Armiento, G Nardone, O Nagano, H Saya, **M Romano**, JR Goldenring. **UEG Journal** 2017; 5:37-44. **IF: 2.08**
- 120) The influence of interoceptive awareness on functional connectivity in patients with irritable bowel syndrome. Longarzo M, Quarantelli M, Aiello M, **Romano M**, Del Prete A, Cimminiello C, Coccozza S, Olivo G, Loguercio C, Trojano L, Grossi D. **Brain Imaging and Behavior** 2017; 11: 1117-1128. **IF:**
- 121) Multi matrix system mesalazine plus rectal mesalazine in the treatment of mild to moderately active ulcerative proctitis. Cuomo A, Sgambato D, D'Auria MV, Miranda A, Ferrante E, **Romano M**. **Dig Dis.** 2018;36:130-135.

## Review Articles

1. Roles for transforming growth factor-alpha in the stomach. R.J. Coffey, **M. Romano**, J. Goldenring. *J Clin Gastroenterol* 21 (suppl 2): S36-S39, 1995. **IF.:3.2**
2. Molecular response of gastric epithelial cells to *Helicobacter pylori*-induced damage. R. Zarrilli, V. Ricci, **M. Romano**. *Cell Microbiol* 1: 93-99, 1999. **IF.: 4.81**
3. Voyage of *Helicobacter pylori* in human stomach: Odyssey of a bacterium. V. Ricci, R. Zarrilli, **M. Romano**. *Digest Liver Dis* 34: 2-8; 2002. **IF.: 3.16**
4. Eradication of *Helicobacter pylori*: a clinical update. **M. Romano**, A. Cuomo. *MedGenMed* 6: 19, 2004.
5. *Helicobacter pylori*-related gastric carcinogenesis - implications for chemoprevention. **M. Romano**, V. Ricci, R. Zarrilli. *Nat Clin Pract Gastroenterol Hepatol* (ora Nat Rev Gastroenterol Hepatol) 3: 622-632, 2006 . **IF: 10.43**
6. Crohn's disease and its muco-cutaneous involvement. E Ruocco, A Cuomo, R Salerno, V Ruocco, **M Romano**, A Baroni. *SKINmed* 6:179-185, 2007.
7. Fat: a matter of disturbance for the immune system. A. Federico\*, E. D'Aiuto, F. Borriello, A.G. Gravina, **M. Romano\***, R. De Palma\*. *World J Gastroenterol* 16: 4762-4772, 2010. **IF: 2.55. \*: Equal contributors.**
8. Molecular cross-talk between *Helicobacter pylori* and human gastric mucosa. V Ricci,\* **M Romano\***,\* P Boquet\*. *World J Gastroenterol* 2011; 17: 1383-1399, 2011. **IF: 2.55. \*: Equal contributors.**
9. Nutraceuticals for protection and healing of gastrointestinal mucosa. **Romano M**, Vitaglione P, Sellitto S, D'Argenio G. *Curr Med Chem* 19: 109-117, 2012. **IF: 4.07.**
10. *Helicobacter pylori* gamma-glutamyl transpeptidase and its pathogenic role. V Ricci, M Giannouli, **M Romano**, R Zarrilli. *World J Gastroenterol* 20: 630-638, 2014 **IF: 2.55.**
11. Eradication of *Helicobacter pylori* infection: which regimen first? A Federico, A G Gravina, A Miranda, C Loguercio, **M Romano**. *World J Gastroenterol* 20: 665-672, 2014 **IF: 2.55.**
12. The impact of translational research on gastroenterology. Di Sabatino A, Moschetta A, Conte D, Tiribelli C; Translational Committee of the Italian Society of Gastroenterology (SIGE), Caprioli FA, Fabris L, Fantini MC, Frulloni L, Monteleone G, **Romano M**, Sarnelli G, Baroni GS. *Dig Liver Dis*; 46:293-294, 2014. **IF: 3.16**
13. L'eradicazione della infezione da *Helicobacter pylori*. F. Bazzoli e **M. Romano**. *Giorn Ital End Dig* 2014; 37:173-176.
14. Crohn's disease and the skin. AG Gravina, A Miranda, D Sgambato, **M Romano**. *United Eur Gastroenterol J*. 2016; 4: 165-171. **IF: 2.08**
15. The effects of alcohol on gastrointestinal tract, liver and pancreas: evidence-based suggestions for clinical management. Federico A, Cotticelli G, Festi D, Schiumerini R, Addolorato G, Ferrulli A, Merli M, Lucidi C, Milani S, Panella C, Domenico M, Vantini I, Benini L, Ubaldi F, **Romano M**, Loguercio C. *Eur Rev Med Pharmacol Sci* 19: 1922-1940, 2015. **IF: 0.99.**
16. Gut-brain axis in gastric mucosal damage and protection. D Sgambato, A Capuano, MG Sullo, A Miranda, A Federico, **M Romano**. *Current Neuropharmacol* 2016; 14:959-966
17. The role of stress in inflammatory bowel diseases. Sgambato D, Miranda A, Ranaldo R, Federico A, **Romano M**. *Curr Pharm Des*. 2017;23:3997-4002.

## Case Reports

1. Procoagulant activities in a patient with peritoneal metastasis from a pancreatic neuroendocrine tumor: a case report. P. Di Micco, A. Federico, D. De Lucia, I. de Sio, A. Niglio, **M. Romano**. *Exp Oncol* 24: 213-215, 2002.
2. Stroke due to left carotid thrombosis in moderate OHSS: a case report. P. Di Micco, M. D'Uva, **M. Romano**, B. Di Micco, A. Niglio. *Thromb Haemost* 90: 957-960, 2003. **IF: 6.1**.
3. Massive gastric ulceration following trans-arterial chemoembolization for hepatocellular carcinoma. A. Morante, M. Romano, I. de Sio, A. Cuomo, A. Cozzolino, C. Mucherino, R. Salerno, C. Del Vecchio Blanco, **M. Romano**. *Gastrointest Endosc* 63: 718-7209, 2006. **IF: 5.21**
4. Multiple lymphomatous polyposis of the entire GU tract: report of two cases. A. De Renzo, F. Perna, **M. Romano**, I. de Sio, A. Lucania, A. Iacono, G. De Rosa, M. Picardi, F. Pane, L. Del Vecchio, B. Rotoli. *Haema* 9: 282-285, 2006.
5. Unexpected finding of laparoscopic appendectomy: appendix MALT lymphoma in children. A. Marte, MD Sabbatino, P. Cautiero, M. Accardo, **M. Romano**, P. Parmeggiani. *Pediatr Surg Int* 24: 471-473, 2008. **IF: 1.22**.
6. Ulcerative colitis associated with leukocytoclastic vasculitis of the skin. F. Tripodi Cutrì, R. Salerno, A. Lo Schiavo, A.G. Gravina, **M. Romano**, E. Ruocco. *Dig Liv Dis* 41: e42-44, 2009. **IF: 3.16**.
7. Gastric xanthomatosis associated with gastric intestinal metaplasia in a dyspeptic patient AG Gravina, A. Iacono, I. Alagia, FP D'Armiento, S. Sansone, **M. Romano**. *Dig Liv Dis* 41:765, 2009. **IF: 3.15**.
8. Endoscopic diagnosis of rectal teratoma in a young woman with constipation and positive fecal occult blood test. A. Federico, AG Gravina, A. Tiso, A. Miranda, FP D'Armiento, M. Mascolo, S. Maurea, **M. Romano**. *Endoscopy* 42 (Suppl 2): E254-E255, 2010. **IF: 5.73**
9. Incidental diagnosis of stromal tumor of the stomach by percutaneous ultrasound-guided biopsy. I. de Sio, AG Gravina, A. Federico, G. Cotticelli, FP D'Armiento, **M. Romano**. *J Gastrointest Liver Dis* 19:465-467, 2010. **IF: 1.81**
10. Colonic angiodysplasia with adenomatous epithelial foci. A. Federico, P. Esposito, AG Gravina, L. Martorelli, G. Esposito, **M. Romano**. *J Gastrointest Liver Dis* 2011; 20:347. **IF: 1.85**
11. Liver failure in an obese middle-aged woman after biliointestinal bypass. Sgambato D, Cotticelli G, de Sio I, Funaro A, Del Prete A, de Sio C, Romano L, Federico A, Miranda A, Gravina AG, Loguercio C, **Romano M**. *World J Clin Cases* 2013; 1:52-55.
12. Cyclic vomiting in a young patient with superior mesenteric artery syndrome. G. Cotticelli, A.G. Gravina, A. Miranda, D. Sgambato, A. Funaro, R. Scalera, C. de Sio, L. Romano, A. Federico, M. Romano\*, **Romano M**. *Acta Gastroenterol Belg* 2013; 76:351-352; **IF:0.58**
13. Secondary extramedullary plasmacytoma of the duodenum: an unusual endoscopic presentation. AG Gravina, A. Federico, A. Sica, FP D'Armiento, MG Ferrara, U. Falcone, M. Dallio, D. Cozzolino, S. Guastafierro, C. Loguercio, **M. Romano**. *Gastroenterol Res* 6:110-111; **2013**
14. The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. Lebaro R, Rosato V, Masarone M, **Romano M**, Persico M. *BMC Res Notes* 7:59, 2014.
15. Skin adverse events during dual and triple therapy for HCV-related cirrhosis. Federico A, Sgambato D, Cotticelli G, Gravina AG, Dallio M, Beneduce F, Ruocco E, **Romano M**, Loguercio C. *Hepat Mon* 14(3): e16632, 2014. **IF: 1.24**
16. Sclerotherapy for the treatment of gastric antral ectasia in case of contraindication to argon plasma coagulation. Zulli C, Esposito P, **Romano M**, Russo MI, Del Prete A. *JSM Gastroenterol Hepatol* 3: 1042, 2015.
17. Refractory gastric antral vascular ectasia: a new endoscopic approach. Zulli C, Del Prete A, Romano M, Esposito F, Amato MR, Esposito P. *Eur Rev Med Pharmacol Sci*; 19: 4119-4122, 2015.

## Meeting Proceedings

1. VacA and ammonia in *Helicobacter pylori*-induced cell vacuolation. Deciphering the chicken or egg relationship. P. Sommi, R. Fiocca, **M. Romano**, V. Ricci. **Gastroenterol Int** 10 (suppl 4): 5-8, 1997.
2. *Helicobacter pylori* inhibits gastric mucosal repair-related events. **M. Romano**, V. Ricci, P. Sommi, R. Zarrilli. **Gastroenterol Int** 10 (suppl 4): 9-12, 1997.
3. *Helicobacter pylori* and gastric mucosal repair-related events: an *in vitro* study. **M. Romano**, V. Ricci, P. Sommi, R. Zarrilli. In: G. Budillon and G. Nardone, Eds. **Helicobacter pylori: From Basic Science to Clinical Management**. Officine Grafiche Napoletane F. Giannini e Figli, Napoli, pag. 41-46, 1997.
4. *Helicobacter pylori* and nonsteroidal anti-inflammatory drugs. S. Fiorucci, **M. Romano**. **Digest Liver Dis** 32 (Suppl 3): S211-S213, 2000. **I.F.: 3.16**
5. The vacuolating cytotoxin of *Helicobacter pylori*: a few answers, many questions. V. Ricci, P. Sommi, **M. Romano**. **Digest Liver Dis** 32 (Suppl 3): S178-S181, 2000. **I.F.: 3.16**
6. Fibrinolysis in non-metastatic gastric cancer. P Di Micco, A Niglio, F Russo, T Izzo, G Chirico, P Iodice, G Castaldo, **M Romano**, R Torella, B Di Micco. In S Cocchieri, G Genuini, G Palareti, D Prisco, Editors, 17th International Congress on Thrombosis, Monduzzi Editore, International Proceedings Division, page 37-40, 2002.
7. Sequential therapy for eradication of *Helicobacter pylori* infection. A. Federico, AG Gravina, A Miranda, L Gaeta, R Zagaria, **M Romano**. **Ciujul Medical** 83 (Suppl 2): 16-20, 2010.
8. Studio della flora microbica intestinale. Miranda A, Zagaria R, Gravina AG, Romano M. In: Ruolo della Flora Batterica nella Patologia Intestinale. Mediserve, Napoli page 9-15, 2012.

## Research Letters (dati originali presentati in forma di short report e sottoposti a peer review)

1. Alanine aminotransferase measurements and histological disease in hepatitis C. M. Persico and **M. Romano**. **Lancet** 342: 1369-1370, 1993. **I.F.: 39.06**
2. IgM anti-HCV core in HCV-RNA positive subjects with and without chronic liver disease. N. Caporaso, F. Morisco, **M. Romano**, M. Persico, I. de Sio, C. Tuccillo. **Ital J Gastroenterol (ora Dig Liver Dis)** 26: 347-348, 1994. **I.F.: 3.16**
3. HCV infection and hepatocellular carcinoma in cirrhotics: what is the linkage? M. Coltorti, N. Caporaso, M. Persico, I. de Sio, R. Marmo, F. Morisco, C. Tuccillo, **M. Romano**. **Dig Dis Sci** 39: 1596-1597, 1994. **I.F.: 2.26**
4. Decreased gastroduodenal mucosal concentration of transforming growth factor  $\alpha$  in *Helicobacter pylori*-infected dyspeptic patients. M. Persico, R. Zarrilli, R. Suozzo, C. Tuccillo, V. Ricci, **M. Romano**. **Am J Gastroenterol** 12: 2963-2964, 1998. **I.F.: 7.55**
5. Seven days of ranitidine bismuth citrate plus two antimicrobials for *H. pylori* eradication. M. Delle Cave, L.M. Vitale, F. Beneduce, P. Ciamarra, R. Marmo, C. Del Vecchio Blanco, **M. Romano**. **Ital J Gastroenterol Hepatol (ora Dig Liver Dis)** 31: 265, 1999. **I.F.: 3.16**
6. Increased COX-2, but not COX-1, mRNA expression in *Helicobacter pylori* gastritis. R. Zarrilli, C. Tuccillo, M. Santangelo, G. Nardone, **M. Romano**. **Am J Gastroenterology** 94: 3376-3378, 1999. **I.F.: 7.55**
7. Pretreatment antimicrobial-susceptibility testing in the eradication of *Helicobacter pylori* infection. **M. Romano**, M.R. Iovene, F. Montella L.M. Vitale, T. De Simone, C. Del Vecchio Blanco. **Am J Gastroenterol** 95: 3317-3318, 2000. **I.F.: 7.55**
8. Proximal deep venous thrombosis occurring after sudden clopidogrel suspension. B. Di Micco, G. Di Micco, A. Niglio, **M. Romano**, P. Di Micco. **Eur J Clin Pharmacol** 60: 63-64, 2004. **I.F. : 2.74**

## Book Chapters

- 1) La epatopatia cronica da alcol: problemi clinico-evolutivi **M. Romano** and M. Coltorti. In: M. Cecanti, T. Chiaroni, A. De Lorenzo, G. Gasbarrini, Eds. **Patologia da Alcole**. Aiello Editore, Cosenza, pag 47-63, 1985.
- 2) Intravascular oesophageal variceal pressure: correlation with endoscopic appearance of varices. D. Taranto, R. Suozzo, **M. Romano**, R. Marmo, N. Caporaso, C. Del Vecchio Blanco, M. Coltorti In P. Gentilini and M.U. Dianzani, Eds. **Chronic liver damage**. Elsevier Science Publishers Biomedical Division (BV), New York, NY, pag. 217-222, 1990.
- 3) Noninvasive diagnosis of compensated liver cirrhosis: multivariate analysis of weights of clinical, biochemical, and ultrasonographic variables. R. Marmo, N. Caporaso, A. Peduto, **M. Romano**, I. de Sio, M. Coltorti. In G. Molino and A. Avagnina, Eds. **Systematic and quantitative hepatology - Pathophysiological and methodological aspects**. Masson SpA Milano, pag. 297-307, 1990.
- 4) HBsAg carriers: evaluation of risk factors for liver disease. N. Caporaso, I. de Sio, **M. Romano**, R. Suozzo, F. Morisco, C. D'Agostino, S. Amato, M. Coltorti. In: O. Schiraldi, G. Pastore, and P. Dentico, Eds. **Progress and Prospects in Viral Hepatitis**. Gerni Editore, Foggia; pag. 61-65, 1991.
- 5) Malattie dello stomaco e del duodeno - Ulcera peptica. **M. Romano**, N. Caporaso, M. Coltorti. In: B. Bizzi e M. Trabucchi, Eds. **Farmacoterapia**, UTET, Torino, pag. 3726-3738, 1995.
- 6) Malattie dello stomaco e del duodeno - Gastriti. **M. Romano**, N. Caporaso, M. Coltorti. In: B. Bizzi e M. Trabucchi, Eds. **Farmacoterapia**, UTET, Torino, pag. 3738-3742, 1995.
- 7) Malattie dello stomaco e del duodeno - Dispepsia non-ulcerosa o funzionale. **M. Romano**, N. Caporaso, M. Coltorti. In: B. Bizzi e M. Trabucchi, Eds. **Farmacoterapia**, UTET, Torino, pag. 3742-3744, 1995.
- 8) Malattie dello stomaco e del duodeno - Sequele e sindromi post-gastrectomia. **M. Romano**, N. Caporaso, M. Coltorti. In: B. Bizzi e M. Trabucchi, Eds. **Farmacoterapia**, UTET, Torino, pag. 3744-3747, 1995.
- 9) Malattie dello stomaco e del duodeno - Tumori dello stomaco. **M. Romano**, N. Caporaso, M. Coltorti. In: B. Bizzi e M. Trabucchi, Eds. **Farmacoterapia**, UTET, Torino, pag. 3747-3749, 1995.
- 10) Malattie dello stomaco e del duodeno - Emorragie gastriche. N. Caporaso, **M. Romano**, M. Coltorti. In: B. Bizzi M. Trabucchi, Eds. **Farmacoterapia**, UTET, Torino, pag. 3756-3759, 1995.
- 11) Meccanismi di danno e fattori di protezione della mucosa gastrica. **M. Romano**. In: C. Del Vecchio Blanco, Ed. **Clinica e Terapia delle Malattie Acido-Correlate del Tratto Digestivo Superiore**. Raffaello Cortina Editore, Milano, pag. 13-41, 1997.
- 12) Le gastriti acute e croniche. **M. Romano**, L. Vitale, F. Beneduce. In: C. Del Vecchio Blanco, Ed. **Clinica e Terapia delle Malattie Acido-Correlate del Tratto Digestivo Superiore**. Raffaello Cortina Editore, Milano, pag.165-187, 1997.
- 13) Role for transforming growth factor alpha in gastric mucosal protection and adaptation to aspirin. **M. Romano** and R.J. Coffey. In: R. Cheli, G. Iaquinto, S. Szabo, Eds. **Gastroduodenal mucosal damage: problems of protection and healing**. Mediserve, Napoli, pag.101-110, 1997.
- 14) Growth factors and reparative mechanisms in the gastrointestinal tract. **M. Romano** and C. Del Vecchio Blanco. In: A. Morelli, C. Surrenti, S. Fiorucci, L. Santucci, Eds. **Advances in gastrointestinal inflammation**. InterScience Publishing Co LDT, London, UK, pag. 127-152, 1999.
- 15) Disordini motori dell'esofago. P. Ciamarra e **M. Romano**. In: C. Del Vecchio Blanco, Ed. **Malattie dell'Apparato Digerente**. Idelson-Gnocchi, Napoli 2001, pag 25-31

- 16) Dispepsia. A. Cuomo, T. De Simone, **M. Romano**. In: C. Del Vecchio Blanco, Ed. **Malattie dell'Apparato Digerente**. Idelson-Gnocchi, Napoli 2001, pag 33-38.
- 17) Esofagiti infettive. P. Ciamarra e M. **Romano**. In: C. el Vecchio Blanco, Ed. **Malattie dell'Apparato Digerente**. Idelson-Gnocchi, Napoli 2001, pag 47-51.
- 18) Gastriti. F. Beneduce, T. De Simone, L.Vitale, **M. Romano**. In: C. Del Vecchio Blanco, Ed. Del Vecchio Blanco, Ed. **Malattie dell'Apparato Digerente**. Idelson-Gnocchi, Napoli 2001, pag 53-59.
- 19) Malattia da reflusso gastroesofageo. A. Cuomo e **M. Romano**. In: C. Del Vecchio Blanco, Ed. **Malattie dell'Apparato Digerente**. Idelson-Gnocchi, Napoli 2001, pag 73-85.
- 20) Malattie infiammatorie croniche intestinali. A. Cuomo, T. De Simone, **M. Romano**. In: C. Del Vecchio Blanco, Ed. **Malattie dell'Apparato Digerente**. Idelson-Gnocchi, Napoli 2001, pag 87-98.
- 21) Ulcera peptica gastrica e duodenale. A. Cuomo e **M. Romano**. In: C. Del Vecchio Blanco, Ed. **Malattie dell'Apparato Digerente**. Idelson-Gnocchi, Napoli 2001, pag 183-192.
- 22) Disordini motori dell'esofago. R. Penagini e **M. Romano**. In: **UNIGASTRO, Malattie dell'Apparato Digerente**, UTET, Torino 2003, pag 139-146.
- 23) Pharmacotherapy of *Helicobacter pylori*-associated gastritis. **M. Romano** and A. Cuomo. In: A. Guglietta Ed. **Pharmacotherapy of Gastrointestinal Inflammation**. Birkhauser Verlag AG, Basel 2003, page 1-16.
- 24) La Malattia da Reflusso Gastroesofageo. A. Cuomo, V. Gallo e **M. Romano** eds. Cuzzolin Editore, Napoli 2004.
- 25) Meccanismi patogenetici nella malattia da reflusso gastroesofageo. C. Mucherino, R. Capasso, R. Salerno, A. Morante, **M. Romano**. In: A. Papparella e P. Parmeggiani, Eds. **Anomalie di sviluppo dell'esofago in età pediatrica**. G. De Nicola, Napoli 2005, pag:17-22.
- 26) Disordini motori e diverticoli dell'esofago. **M. Romano**, R. Penagini. In: UNIGASTRO ed: Manuale di Gastroenterologia, Pacini Editore, Ospedaletto (PI) 2010, pag 132-140.
- 27) Aspetti alimentari, stato nutrizionale e malattie dell'apparato digerente – Interazione nell'età evolutiva e nell'adulto. A Federico, A Costantino, C Loguercio, **M Romano**. G. De Nicola Editore, Napoli 2010.
- 28) Infezione da *Helicobacter pylori*: fisiopatologia e clinica. **M Romano**, F Micera, P Schettino, A Miranda, AG Gravina. Promoidea Srl, Napoli, 2010.
- 29) Le emorragie digestive. P Esposito, MI Russo, F Esposito, P Sperlongano, **M Romano**. In: P Esposito, Ed. Le procedure diagnostiche e terapeutiche in endoscopia digestiva. Momento Medico, Salerno, 2011, pag 175-191.
- 30) L'utilizzo di farmaci anti-TNF nella malattia di Crohn. AG Gravina, A Federico, M. Romano. G. De Nicola Editore, Napoli 2012.
- 31) Esofagiti non da reflusso. A. Federico e M Romano. In: UNIGASTRO ed: Manuale di Gastroenterologia, Editrice Gastroenterologica Italiana, Roma 2013, pag 147-150.
- 32) Linee guida per la gestione dell'infezione da *Helicobacter pylori* in Italia Zagari RM Annibale B... **Romano M**. EGI, Roma 2016

## Financial Support for Research

- “Role of EGF-related growth factors in the proliferative response of gastroie epithelial cells to *H pylori* infection in Vivo and in Vitro”  
**C.N.R. research grant for 1996 , 1998 and 1999**
- “Expression of cyclooxygenase-2 in the gastric mucosa of *H. pylori* infected patients  
**BYK GULDEN Award in Gastroenterology 1999**
- "Espressione di Fattori di Crescita EGF-correlati nella Mucosa Gastrica di Soggetti con Infezione da *H. pylori*" (primo anno)  
**Finanziamento Fondi Ateneo per il 2000**
- Mechanisms of chemoprevention and chemoresistance in gastric carcinogenesis related to *H pylori* infection  
**PRIN 2004** project prot. n. 2004065448
- Eicosapentanoic acid-free fatty acid prevents inflammation and cancer in colitis-associated colorectal cancer (Dr Luigi Ricciardiello Principal Investigator)  
**AIRC 2010-2012 (210,000 Euro)**
- Apple and olive oil polyphenol extracts in th eprevention of colo-rectal cancer: Preclinicla study in animals **LILT 2010 (130,000 Euro).**
- Optimization of personalized therapy with molecular target drugs in colorectal cancer (**PI: Prof. F. Ciardiello**)  
**i PRIN 2010; codice 2010F84SL7 Decreto Direttoriale 23 ottobre 2012 n. 719 ( 932.156 Euro).**



## Experience in Clinical Trials

1. A randomised, double-blind multicentre dose-finding phase II b study for 8 weeks treatment with AZD0865 25, 50, 75 mg and esomeprazole 40 mg, given orally once daily for the healing of erosive esophagitis in adult subjects with GERD with erosive esophagitis according to the LA classification in adult subjects (ASTRAZENECA, 2004)
2. A 4 week randomised, double-blind multicentre dose-finding phase IIb study with AZD0865 25, 50, and 75 mg compared to esomeprazole 20 mg both given orally once daily for the treatment of GERD without erosive esophagitis according to the LA classification in adult subjects (ASTRAZENECA 2004)
3. A randomized, double blind placebo-controlled study to assess the prevention of low dose acetylsalicylic acid associated gastroduodenal lesion and upper gastrointestinal symptoms in patients taking esomeprazole 20 mg once daily for 26 weeks (ASTERIX Study) (ASTRAZENECA 2004)
4. A D5170C00001 phase 2a study to evaluate the efficacy and safety of MEDI2070 in subjects with moderate to severe Crohn's disease who have failed or are intolerant to anti-tumor necrosis factor-alpha therapy. (Astra-Zeneca 2013)

